Literature DB >> 22781769

[Clinical features and screening of ACVRL1 gene in II hereditary hemorrhagic telangiectasia].

Jing-jie Jia1, Jing Zhang, Li-dong Zhao, Xue-jun Zhou, Jing Cheng, Hui-jun Yuan, Hong-tian Wang.   

Abstract

OBJECTIVE: To analyze the clinical features and pathogenic gene of the patients with hereditary hemorrhagic telangiectasia (HHT).
METHODS: The clinical features of 3 HHT families were collected. And the patients were diagnosed according to clinical diagnostic analyzed criteria of HHT, the ACVRL1 gene screened and the conservation of mutation protein.
RESULTS: Three probands and 1 patient were diagnostic for HHT and 2 patients were suspected. In family I, there was a missense mutation of ACVRL1 gene in c.287A > G on 2 patients, leading to the transferal of amino acids from Asn to Ser at 96(th) place. In family II, there was a missense mutation of c.1271C > T on ACVRL1 in 2 patients, leading to the transfer of amino acids from Pro to Leu at 424(th) place. In family III, there was a deletion mutation of c.147delC on ACVRL1 so as to produce only the former 53 amino acids of ALK1 protein. Through an analysis of multi-species conservation, the mutations were conserved between multiple species. By querying the National Center for Biotechnology Information (NCBI) database, we confirmed that the mutation was not of a single nucleotide polymorphism (SNP).
CONCLUSION: The genetic screening of HHT patients may identify their virulence gene. And genetic screening of their offspring is helpful for the early diagnosis and prevention before disease onset.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22781769

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  1 in total

1.  NAPG mutation in family members with hereditary hemorrhagic telangiectasia in China.

Authors:  Yu Xu; Yong-Biao Zhang; Li-Jun Liang; Jia-Li Tian; Jin-Ming Lin; Pan-Pan Wang; Rong-Hui Li; Ming-Liang Gu; Zhan-Cheng Gao
Journal:  BMC Pulm Med       Date:  2021-06-10       Impact factor: 3.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.